Takeda positive on norovirus vaccine despite missed endpoint
This article was originally published in Scrip
Takeda appears ready to press ahead with the development of its first-in-class candidate vaccine for norovirus, saying it is encouraged by an early clinical trial with the bivalent product despite the challenge study missing its primary endpoint.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.